FDA Approved: ONDANSETRON — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)

View source ↗

Summary

FDA approved a supplemental application for ondansetron submitted by Qilu Pharmaceutical Co., Ltd. (ANDA 203711).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting
• Postoperative Nausea and Vomiting
• Radiation-induced Nausea and Vomiting

Drugs mentioned

• Ondansetron (ondansetron)

Snippet

SUPPL AP for ONDANSETRON (ONDANSETRON)